Telix Pharmaceuticals
Telix Pharmaceuticals Limited, commonly referred to as Telix, is a pioneering biopharmaceutical company headquartered in the United States, with significant operations across Europe and Asia-Pacific. Founded in 2015, Telix focuses on the development of innovative radiopharmaceuticals for the diagnosis and treatment of cancer, particularly in areas such as prostate and kidney cancers. The company’s core products, including its lead candidate TLX591 (also known as Illuccix), utilise advanced radiolabelled technologies that enhance precision in cancer imaging and therapy. Telix has established a strong market position, marked by notable achievements such as successful clinical trials and strategic partnerships that bolster its research and development capabilities. With a commitment to improving patient outcomes, Telix Pharmaceuticals is at the forefront of the evolving landscape of oncology therapeutics.
DitchCarbon Score
How does Telix Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Telix Pharmaceuticals's score of 25 is lower than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Telix Pharmaceuticals's reported carbon emissions
Telix Pharmaceuticals, headquartered in the US, currently does not report any specific carbon emissions data, as there are no available figures for emissions in kg CO2e. Additionally, the company has not established any documented reduction targets or climate pledges. As of now, Telix Pharmaceuticals does not inherit emissions data from any parent or related organizations, indicating that their climate commitments and emissions reporting are independent. Without specific emissions data or reduction initiatives, it is unclear how the company is addressing its carbon footprint or contributing to climate action within the pharmaceutical industry. In the absence of concrete data, it is essential for Telix Pharmaceuticals to consider setting measurable climate targets and engaging in transparent reporting to align with industry standards and expectations for sustainability.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Telix Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
